

Gary H Lyman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2789224/gary-h-lyman-publications-by-year.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

527
papers

44,583
citations

98
h-index

204
g-index

553
ext. papers

51,239
ext. citations

6.1
avg, IF

7.4
L-index

#	Paper	IF	Citations
527	Use of Biosimilar Medications in Oncology.. <i>JCO Oncology Practice</i> , 2022 , OP2100771	2.3	1
526	Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD.. <i>BMC Health Services Research</i> , 2022 , 22, 432	2.9	0
525	Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. <i>Cancer Investigation</i> , 2021 , 1-9	2.1	7
524	Examining pain among non-Hispanic Black and non-Hispanic White patients with cancer visiting emergency departments: CONCERN (Comprehensive Oncologic Emergencies Research Network). <i>Academic Emergency Medicine</i> , 2021 ,	3.4	
523	Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. <i>Cancer Investigation</i> , 2021 , 1-9	2.1	0
522	Challenges of Cancer Immunotherapy during the COVID-19 Pandemic. <i>Cancer Investigation</i> , 2021 , 39, 115-119	2.1	2
521	Aligning Cancer Clinical Trials With Cancer Burden: Need for Greater Global Leadership, Resources, and Vision. <i>JAMA Oncology</i> , 2021 , 7, 357-358	13.4	1
520	Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. <i>Cancer Investigation</i> , 2021 , 39, 315-320	2.1	0
519	Medications in Single-Dose Vials and Implications of Discarded Injectible Drugs: A National Academies Report. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1507-1508	27.4	1
518	Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2037-2048	2.2	8
517	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021 , 4, 464-472	6.7	9
516	Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 1145-1159	3.5	1
515	Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era. <i>Frontiers in Oncology</i> , 2021 , 11, 697908	5.3	3
514	Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies. <i>JCO Oncology Practice</i> , 2021 , 17, e406-e415	2.3	4
513	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , 39, 685-693	2.2	28
512	Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1203-1210	1.9	1
511	Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. <i>Supportive Care in Cancer</i> , 2021 , 29, 2179-2186	3.9	7

510	Expenditures among young adults with acute lymphoblastic leukemia by site of care. <i>Cancer</i> , 2021 , 127, 1901-1911	6.4	2
509	Cancer pain management in the emergency department: a multicenter prospective observational trial of the Comprehensive Oncologic Emergencies Research Network (CONCERN). <i>Supportive Care in Cancer</i> , 2021 , 29, 4543-4553	3.9	3
508	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. <i>Blood Advances</i> , 2021 , 5, 927-974	7.8	96
507	Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer. <i>Cancer Investigation</i> , 2021 , 39, 205-213	2.1	7
506	Opportunities and Challenges of Observational Studies and Randomized Controlled Trials for Evaluating the Therapeutic Efficacy of COVID-19 Convalescent Plasma. <i>Cancer Investigation</i> , 2021 , 39, 449-456	2.1	1
505	The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2522-2532	15.4	6
504	Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?. <i>Frontiers in Immunology</i> , 2021 , 12, 706186	8.4	3
503	Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. <i>JCO Oncology Practice</i> , 2021 , 17, e1235-e1245	2.3	4
502	COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response. <i>JAMA Oncology</i> , 2021 ,	13.4	10
501	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. <i>Blood Advances</i> , 2021 , 5, 4721-4726	7.8	3
500	Healthcare costs of patients with cancer stratified by Khorana score risk levels. <i>Journal of Medical Economics</i> , 2021 , 24, 866-873	2.4	
499	Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. <i>Cancer</i> , 2021 , 127, 1459-1468	6.4	47
498	Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. <i>BMC Medical Research Methodology</i> , 2020 , 20, 113	4.7	12
497	Anticoagulants for the treatment of venous thromboembolism in patients with cancer: A comprehensive systematic review, pairwise and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 103005	7	3
496	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-1918	18.8	10
495	Crowdsourcing a crisis response for COVID-19 in oncology. <i>Nature Cancer</i> , 2020 , 1-4	15.4	43
494	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1940-1951	15.4	24
493	NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 12-22	7.3	44

492	Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 1-4	7.3	16
491	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020 , 204, 63-70	2.5	11
490	Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. <i>Current Medical Research and Opinion</i> , 2020 , 36, 483-495	2.5	6
489	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020 , 126, 1208-1216	6.4	37
488	The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2020 , 99, 121-126	3	12
487	Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia. <i>JAMA Oncology</i> , 2020 , 6, 1969-1971	13.4	4
486	Antiemetics: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2782-2797	2.2	63
485	Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 1309-1315	3.6	1
484	Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis. <i>Thrombosis Research</i> , 2020 , 191 Suppl 1, S79-S84	8.2	9
483	Crowdsourcing in Crisis: Rising to the Occasion. <i>JCO Clinical Cancer Informatics</i> , 2020 , 4, 551-554	5.2	6
482	Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. <i>Targeted Oncology</i> , 2020 , 15, 467-475	5	3
481	Randomized Controlled Trials Versus Real-World Data in the COVID-19 Era: A False Narrative. <i>Cancer Investigation</i> , 2020 , 38, 537-542	2.1	5
480	COVID-19, Cancer, and Consequences: Where Are We Now?. <i>Cancer Investigation</i> , 2020 , 38, 431-435	2.1	4
479	Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels. <i>Cancer Medicine</i> , 2020 , 9, 8062-8073	4.8	7
478	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020 , 7, e746-e755	14.6	8
477	Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism. <i>Blood Advances</i> , 2020 , 4, 4045-4051	7.8	0
476	Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. <i>Supportive Care in Cancer</i> , 2020 , 28, 925-932	3.9	25
475	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2020 , 38, 496-520	2.2	479

474	Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. <i>Cancer</i> , 2020 , 126, 1736-1748	6.4	11
473	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2916-2946	2.2	56
472	Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. <i>Thrombosis Research</i> , 2019 , 180, 37-42	8.2	8
471	Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care. <i>BMC Medical Research Methodology</i> , 2019 , 19, 119	4.7	14
470	Febrile Neutropenia: An Ounce of Prevention or a Pound of Cure. <i>Journal of Oncology Practice</i> , 2019 , 15, 27-29	3.1	2
469	Analysis of Diagnoses, Symptoms, Medications, and Admissions Among Patients With Cancer Presenting to Emergency Departments. <i>JAMA Network Open</i> , 2019 , 2, e190979	10.4	43
468	Biosimilars: what the oncologist should know. <i>Future Oncology</i> , 2019 , 15, 1147-1165	3.6	13
467	Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study. <i>BMC Cancer</i> , 2019 , 19, 792	4.8	9
466	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2141-2151	15.4	31
465	Validation of the Emergency Severity Index (Version 4) for the Triage of Adult Emergency Department Patients With Active Cancer. <i>Journal of Emergency Medicine</i> , 2019 , 57, 354-361	1.5	12
464	Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 840-847	7.3	46
463	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 720-728	59.2	322
462	Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-10	3.6	2
461	Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019 , 173, 158-163	8.2	149
460	Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. <i>Clinical Breast Cancer</i> , 2018 , 18, 380-386	3	31
459	Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia. <i>Clinical Lung Cancer</i> , 2018 , 19, e163-e169	4.9	18
458	Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). <i>Oncologist</i> , 2018 , 23, 247-255	5.7	42
457	Patient-reported outcomes in acute myeloid leukemia: Where are we now?. <i>Blood Reviews</i> , 2018 , 32, 81-87	11.1	28

456	A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. <i>Supportive Care in Cancer</i> , 2018 , 26, 7-20	3.9	32
455	Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. <i>Thrombosis Research</i> , 2018 , 164 Suppl 1, S112-S118	8.2	63
454	Immune-related Adverse Events in Cancer Patients. <i>Academic Emergency Medicine</i> , 2018 , 25, 819-827	3.4	15
453	Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. <i>BMC Cancer</i> , 2018 , 18, 44	4.8	128
452	Rationale, Opportunities, and Reality of Biosimilar Medications. <i>New England Journal of Medicine</i> , 2018 , 379, 694-695	59.2	7
451	Depression and Health Care Utilization at End of Life Among Older Adults With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2018 , 56, 699-708.e1	4.8	16
450	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018 , 132, LBA-1-LBA-1	2.2	9
449	The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category. <i>Blood</i> , 2018 , 132, 3798-3798	2.2	1
448	Comparative analysis of multigene assays (MGA) effects on chemotherapy (CT) de-escalation for women with N0, ER+ early stage breast cancer (ESBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e12519-e12519	2.2	2
447	Cost of Care at NCI-Designated Comprehensive Cancer Centers Vs. Other Treatment Sites for Young Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2018 , 132, 3531-3531	2.2	
446	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. <i>Annals of Surgical Oncology</i> , 2018 , 25, 356-377	3.1	89
445	Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2018 , 14, 495-499	3.1	15
444	Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study. <i>Journal of Oncology Practice</i> , 2018 , 14, e176-e185	3.1	35
443	Reply to S.D. Lucio. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2127	2.2	
442	Lessons From Reporting National Performance Measures in a Regional Setting: Washington State Community Cancer Care Report. <i>Journal of Oncology Practice</i> , 2018 , 14, e801-e814	3.1	3
441	American Society of Clinical Oncology Statement: Biosimilars in Oncology. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1260-1265	2.2	65
440	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2018 , 14, 242-245	3.1	8
439	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 399-413	2.2	128

438	Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). <i>Journal of Clinical Oncology</i> , 2018 , 36, 2017-2023	2.2	607
437	Oncology Clinical Pathways: Charting the Landscape of Pathway Providers. <i>Journal of Oncology Practice</i> , 2018 , 14, e194-e200	3.1	18
436	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2433-2443	2.2	95
435	American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions. <i>Journal of Global Oncology</i> , 2018 , 4, 1-8	2.6	7
434	Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2647-2655	2.2	145
433	Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 491-497	7.3	11
432	Rationale, Opportunities, and Reality of Biosimilar Medications. <i>New England Journal of Medicine</i> , 2018 , 378, 2036-2044	59.2	41
431	Integrative omics to detect bacteremia in patients with febrile neutropenia. <i>PLoS ONE</i> , 2018 , 13, e0197049	3.7	5
430	Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice. <i>Journal of Oncology Pharmacy Practice</i> , 2017 , 23, 33-42	1.7	2
429	Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 39-52	2.2	2
428	Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: 2016 American Society of Clinical Oncology Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2017 , 13, 196-198	3.1	49
427	Chemotherapy Use at the End of Life in Uganda. <i>Journal of Global Oncology</i> , 2017 , 3, 711-719	2.6	4
426	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017 , 151, 89-95	8.2	93
425	Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment. <i>Cancer</i> , 2017 , 123, 2506-2515	6.4	6
424	Costs, Trends, and Related Factors in Treating Lung Cancer Patients in 67 Hospitals in Guangxi, China. <i>Cancer Investigation</i> , 2017 , 35, 345-357	2.1	3
423	Vascular Complications of Cancer and Cancer Therapy 2017 , 215-240		
422	The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. <i>Supportive Care in Cancer</i> , 2017 , 25, 2619-2629	3.9	27
421	Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. <i>Pharmacoeconomics</i> , 2017 , 35, 425-438	4.4	12

420	Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology. <i>JAMA Oncology</i> , 2017 , 3, 996-998	13.4	109
419	Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017 , 35, 561-564	2.2	239
418	Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. <i>JNCI Cancer Spectrum</i> , 2017 , 1, pkx009	4.6	2
417	American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology. <i>Journal of Oncology Practice</i> , 2017 , 13, 207-210	3.1	23
416	Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1845-1854	2.2	62
415	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3240-3261	2.2	351
414	Reply to L. Del Mastro and A. Prat. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1139	2.2	
413	Emerging Opportunities and Challenges of Biosimilars in Oncology Practice. <i>Journal of Oncology Practice</i> , 2017 , 13, 7s-9s	3.1	4
412	A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1543-1550	7.3	15
411	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. <i>Journal of Comparative Effectiveness Research</i> , 2017 , 6, 461-470	2.1	7
410	Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit. <i>JAMA Oncology</i> , 2017 , 3, 374-381	13.4	42
409	Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor. <i>Supportive Care in Cancer</i> , 2017 , 25, 439-447	3.9	29
408	Predicting neutropenia risk in patients with cancer using electronic data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017 , 24, e129-e135	8.6	11
407	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2135-2145	7	37
406	Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1520-1541	7.3	76
405	Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	2
404	The role of chronic disease in the costs of potentially preventable emergency department use during treatment: A regional study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6505-6505	2.2	1
403	Patterns in provider types and cost of surveillance testing in early-stage breast cancer patients: A regional study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6582-6582	2.2	1

402	Neutropenia related hospitalization risk in lung cancer patients with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18290-e18290	2.2	1
401	Thromboembolic events (TE) among patients with metastatic pancreatic ductal adenocarcinoma (mPDA) after chemotherapy (Chemo).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 280-280	2.2	
400	Out of system (OOS) costs for oncology clinics treating patients with breast, colorectal, and non-small cell lung cancer in Washington state.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5-5	2.2	
399	Systematic reviews and meta-analyses in geriatric oncology.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21517-e21517	2.2	
398	Predictors of advanced imaging use during breast cancer surveillance.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18337-e18337	2.2	
397	Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 283-290	1.9	7
396	Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3872-3879	2.2	16
395	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2925-34	2.2	384
394	Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking Precision Medicine. <i>New England Journal of Medicine</i> , 2016 , 375, 4-6	59.2	73
393	A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. <i>Oncologist</i> , 2016 , 21, 861-7	5.7	44
392	Reply to M.G. McNamara et al and T.H. Oo. <i>Journal of Clinical Oncology</i> , 2016 , 34, 517-8	2.2	
391	Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 483-92	4.1	11
390	Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology. <i>Genetics in Medicine</i> , 2016 , 18, 780-7	8.1	12
389	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Journal of Clinical Oncology</i> , 2016 , 34, 611-35	2.2	500
388	Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs: Pick Your Poison. <i>JAMA Oncology</i> , 2016 , 2, 425-6	13.4	13
387	Antiemetics: American Society of Clinical Oncology Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2016 , 34, 381-6	2.2	150
386	Predictors of Venous Thromboembolism in Colorectal Cancer: Results from a Global Prospective Study. <i>Blood</i> , 2016 , 128, 1422-1422	2.2	1
385	Incidence of bone metastases in U.S. patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e13099-e13099	2.2	3

384	The Quality of Survival (QoS): A concept framework to assist communication and decision making about cancer care.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 78-78	2.2	1
383	Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 32-32	2.2	
382	Value in cancer care: Regional initiative to improve care through data reporting and interventions.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 34-34	2.2	
381	Measuring adherence to a Choosing Wisely recommendation in a regional oncology clinic.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 196-196	2.2	
380	Regional initiative to use data transparency to improve cancer care.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 39-39	2.2	
379	HICOR IQ: Developing a regional oncology metric reporting platform.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 165-165	2.2	
378	Regional engagement to define, report, and use quality metrics to improve palliative care in oncology.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 282-282	2.2	2
377	Global prospective cohort study of factors associated with early mortality in patients with lung cancer undergoing chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9078-9078	2.2	
376	Burden of febrile neutropenia hospitalizations (FNH) in U.S. clinical practice, by use and patterns of colony-stimulating factor prophylaxis (CP).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6568-6568	2.2	
375	End of life services for cancer patients: A population-based evaluation.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6524-6524	2.2	
374	Health care utilization and costs at end of life among patients with leukemia or lymphoma in a regional cancer registry-insurance claims linked database.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 184-184 ^{2,2}		
373	Issues on the Use of White Blood Cell Growth Factors in Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e528-32 ^{7,1}		2
372	Innovations in American Society of Clinical Oncology Practice Guideline Development. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3213-20	2.2	13
371	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , 2016 , 6, e010569	3	14
370	Evaluation and Regulation of Oncology Drug Approval: Finding the Right Balance. <i>JAMA Oncology</i> , 2016 , 2, 728-9	13.4	2
369	Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2061-6	2.2	16
368	Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2416-27	2.2	95
367	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 43-73	220.7	314

366	American Cancer Society Head and Neck Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 203-39	220.7	293
365	Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. <i>Journal of Clinical Oncology</i> , 2015 , 33, 654-6	2.2	534
364	Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors. <i>Journal of Oncology Practice</i> , 2015 , 11, 47-54	3.1	48
363	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2563-77	2.2	599
362	Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3199-212	2.2	488
361	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 996-1000	6.4	105
360	Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. <i>Journal of Oncology Practice</i> , 2015 , 11, e442-4	3.1	97
359	When is good, good enough? Methodological pragmatism for sustainable guideline development. <i>Implementation Science</i> , 2015 , 10, 28	8.4	11
358	Breast cancer screening utilization and understanding of current guidelines among rural U.S. women with private insurance. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 659-67	4.4	11
357	Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. <i>JAMA Oncology</i> , 2015 , 1, 1098-1109	13.4	46
356	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. <i>Genetics in Medicine</i> , 2015 , 17, 63-7	8.1	16
355	Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. <i>JAMA Oncology</i> , 2015 , 1, 158-66	13.4	49
354	Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?. <i>Cancer Medicine</i> , 2015 , 4, 1153-60	4.8	16
353	Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. <i>Blood</i> , 2015 , 126, 2790-7	2.2	37
352	Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1383-93	7.3	55
351	Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 979-86	7.3	13
350	Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, e1-7	7.3	28
349	Baseline Estimates of Adherence to American Society of Clinical Oncology/American Board of Internal Medicine Choosing Wisely Initiative Among Patients With Cancer Enrolled With a Large Regional Commercial Health Insurer. <i>Journal of Oncology Practice</i> , 2015 , 11, 338-43	3.1	24

348	The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. <i>SpringerPlus</i> , 2015 , 4, 396		10
347	Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial. <i>Blood</i> , 2015 , 126, 427-427	2.2	10
346	Evolving Healthcare Quality in Top Tertiary General Hospitals in China during the China Healthcare Reform (2010-2012) from the Perspective of Inpatient Mortality. <i>PLoS ONE</i> , 2015 , 10, e0140568	3.7	7
345	Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens. <i>American Health and Drug Benefits</i> , 2015 , 8, 273-82	1.7	24
344	CoaGlio IV Trial: Randomized, controlled, triple-blind, multinational phase III study of adjuvant prophylactic anticoagulation in patients with glioblastoma WHO IV.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS2079-TPS2079	2.2	
343	Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 190-9	7	147
342	Colony-stimulating factors for chemotherapy-induced febrile neutropenia. <i>The Cochrane Library</i> , 2014 , CD003039	5.2	57
341	Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1362-6	2.2	135
340	Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1365-83	2.2	522
339	Biosimilars: a cure to the U.S. health care cost conundrum?. <i>Blood Reviews</i> , 2014 , 28, 263-8	11.1	16
338	Impact of venous thromboembolism on survival in patients with advanced cancer: an unmet clinical need. <i>Internal and Emergency Medicine</i> , 2014 , 9, 497-9	3.7	7
337	Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1840-50	2.2	367
336	Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. <i>Thrombosis Research</i> , 2014 , 133 Suppl 2, S122-7	8.2	38
335	Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. <i>Journal of Oncology Pharmacy Practice</i> , 2014 , 20, 190-8	1.7	53
334	Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. <i>Annals of Internal Medicine</i> , 2014 , 160, 672-83	8	77
333	Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses. <i>Journal of Medical Economics</i> , 2014 , 17, 32-42	2.4	18
332	Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. <i>Cancer Medicine</i> , 2014 , 3, 434-44	4.8	60
331	Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. <i>Supportive Care in Cancer</i> , 2014 , 22, 3275-85	3.9	18

330	Imagine a world without cancer. <i>BMC Cancer</i> , 2014 , 14, 186	4.8	9
329	Reply to L.k. Griffeth et al and J.E. Battley et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2812-3	2.2	
328	Reply to I.A. Voutsadakis et al and A. Goyal et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3902-4	2.2	5
327	Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014 , 133, 446-53	4.9	7
326	Impact of Comorbidities on Length of Stay and Mortality in Hospitalized Patients with Cancer and Febrile Neutropenia. <i>Blood</i> , 2014 , 124, 2601-2601	2.2	3
325	Predictors of clinically significant bleeding in colorectal cancer: Results from a global prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 558-558	2.2	2
324	A national survey of breast cancer screening in rural America.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6546-6546		
323	Regional initiative to define, collect, and report value metrics in cancer care.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 25-25	2.2	
322	Predictors of early mortality in colorectal cancer patients undergoing chemotherapy: Results from a global prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 532-532	2.2	
321	Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen. <i>Cancer</i> , 2013 , 119, 3703-9	6.4	7
320	Chemotherapy dosing in overweight and obese patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 451-9	19.4	62
319	Update on the Role of Etoposides in Metastatic Breast Cancer. <i>Current Breast Cancer Reports</i> , 2013 , 5, 51-56	0.8	2
318	A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 863-72	4.4	30
317	Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 88, 1-18	7	40
316	Multidisciplinary care of patients with early-stage breast cancer. <i>Surgical Oncology Clinics of North America</i> , 2013 , 22, 299-317	2.7	3
315	Counting the costs of cancer care. <i>Lancet Oncology</i> , 2013 , 14, 1142-3	21.7	9
314	Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2189-204	2.2	640
313	Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies. <i>Journal of Geriatric Oncology</i> , 2013 , 4, 310-8	3.6	14

312	Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2013 , 129, 74-80	4.9	57
311	Appropriate chemotherapy dosing in obese patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 664	19.4	5
310	Comparative effectiveness research in oncology. <i>Oncologist</i> , 2013 , 18, 752-9	5.7	14
309	Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 929-36	9.7	28
308	Reply to T.H. Oo. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4381-2	2.2	3
307	The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Oncology</i> , 2013 , 24, 2475-2484	10.3	122
306	Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. <i>Genetics in Medicine</i> , 2013 , 15, 203-11	8.1	42
305	Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. <i>Oncologist</i> , 2013 , 18, 1321-9	5.7	124
304	American Society of Clinical Oncology 2013 top five list in oncology. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4362-70	2.2	111
303	Will biosimilars gain momentum?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 1291-7	7.3	14
302	Myeloid growth factors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 1266-9	9.3	49
301	Risk Score For Venous Thromboembolism (VTE) In Ambulatory Patients: Impact Of Cancer Type and Risk Score On VTE Incidence, Early Mortality and Progression-Free Survival. <i>Blood</i> , 2013 , 122, 3597-3597	2.2	1
300	Thrombosis and cancer: emerging data for the practicing oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 ,	7.1	14
299	National survey of breast cancer screening in rural America.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 13-13	2.2	2
298	Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , e337-e345	7.1	6
297	Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 81, 296-308	7	18
296	Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. <i>Gynecologic Oncology</i> , 2012 , 125, 625-30	4.9	25
295	Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1553-61	2.2	358

294	Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. <i>Pharmacoeconomics</i> , 2012 , 30, 103-18	4.4	9
293	Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. <i>Annals of Surgical Oncology</i> , 2012 , 19, 3313-24	3.1	84
292	Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. <i>Genetics in Medicine</i> , 2012 , 14, 633-42	8.1	33
291	A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. <i>Value in Health</i> , 2012 , 15, 1014-21	3.3	17
290	Costs associated with febrile neutropenia in the US. <i>Pharmacoeconomics</i> , 2012 , 30, 809-23	4.4	53
289	Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. <i>Pharmacoeconomics</i> , 2012 , 30, 497-511	4.4	18
288	Antiemetic Use in Oncology: Updated Guideline Recommendations from ASCO. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 532-40	7.1	18
287	Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. <i>Cancer</i> , 2012 , 118, 3377-86	6.4	715
286	Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. <i>Cancer</i> , 2012 , 118, 6298-9; author reply 6299-300	6.4	3
285	Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 301-10	4.4	36
284	Reply to P.K.L. Chin et al, P. Chambers et al, and J.H. Beumer et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3898-3899	2.2	
283	Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2912-8	2.2	244
282	Making genuine progress against metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3448-51	2.2	9
281	Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. <i>Journal of Oncology Practice</i> , 2012 , 8, e65-e66	3.1	3
280	Comparative effectiveness research in oncology: an overview. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4181-4	2.2	44
279	Weight-based chemotherapy dosing in obese patients with cancer: back to the future. <i>Journal of Oncology Practice</i> , 2012 , 8, e62-4	3.1	18
278	Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Oncology Practice</i> , 2012 , 8, e59-e61	3.1	22
277	American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3136-40	2.2	118

276	Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. <i>Chemotherapy</i> , 2012 , 58, 8-18	3.2	38
275	Epilogue: the peril and the promise of comparative effectiveness research in oncology. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4282	2.2	2
274	Preventing VTE in Outpatients With Cancer. <i>Chest</i> , 2012 , 142, 265-266	5.3	3
273	Economics of the Recombinant Human Granulocyte Colony-Stimulating Factors 2012 , 409-420		1
272	Current patterns of chemotherapy and supportive care for early-stage breast cancer (ESBC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1062-1062	2.2	
271	Prospective cohort study of chemotherapy-associated toxicity and supportive care in oncology practice.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 9135-9135	2.2	
270	The incidence of venous thromboembolism in cancer patients: a real-world analysis. <i>Clinical Advances in Hematology and Oncology</i> , 2012 , 10, 40-2	0.6	10
269	Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. <i>Medical Care</i> , 2011 , 49, 649-57	3.1	14
268	A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. <i>Current Opinion in Hematology</i> , 2011 , 18, 1-10	3.3	5
267	Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1726-32	8.9	19
266	NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9 Suppl 4, S1-22	7.3	94
265	Myeloid growth factors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 914-32	7.3	23
264	Biosimilars: are they ready for primetime in the United States?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 934-42; quiz 943	7.3	21
263	Systematic Review of 99mTc Human Serum Albumin and 99mTc Sulfur Colloid Studies of Sentinel Lymph Node Biopsy of Cutaneous Melanoma of the Head and Neck. <i>Laryngoscope</i> , 2011 , 121, S106-S106 ^{3,6}		
262	Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 511-20	4.4	7
261	Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011 , 130, 255-66	4.4	13
260	Breast cancer screening with mammography. <i>Current Oncology Reports</i> , 2011 , 13, 63-70	6.3	14
259	Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. <i>Cancer</i> , 2011 , 117, 1917-27	6.4	159

258	Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. <i>Cancer</i> , 2011 , 117, 1334-49	6.4	119
257	Reply to risk of mortality in patients with cancer who experience febrile neutropenia. <i>Cancer</i> , 2011 , 117, 5246-5246	6.4	
256	Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. <i>Cancer Treatment and Research</i> , 2011 , 157, 145-65	3.5	6
255	Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1757-64	2.2	163
254	Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 910-3	9.7	26
253	Antiemetics: american society of clinical oncology clinical practice guideline update. <i>Journal of Oncology Practice</i> , 2011 , 7, 395-8	3.1	44
252	Sentinel node biopsy for head and neck melanoma: a systematic review. <i>Otolaryngology - Head and Neck Surgery</i> , 2011 , 145, 375-82	5.5	92
251	Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1479-87	2.2	148
250	Reply to S. Hapani et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3490-3491	2.2	1
249	Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4189-98	2.2	606
248	Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines. <i>Journal of Oncology Practice</i> , 2011 , 7, 17-8	3.1	8
247	Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines?. <i>Journal of Oncology Practice</i> , 2011 , 7, 398-401	3.1	6
246	Long-term outcomes of myeloid growth factor treatment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 945-52	7.3	12
245	The economics of the hematopoietic growth factors. <i>Cancer Treatment and Research</i> , 2011 , 157, 403-18	3.5	
244	Neutropenia 2011 , 2506-2509		
243	Changing Patterns of Chemotherapy Delivery and Supportive Care for Aggressive B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2011 , 118, 2670-2670	2.2	1
242	Introduction to the hematopoietic growth factors. <i>Cancer Treatment and Research</i> , 2011 , 157, 3-10	3.5	2
241	Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome. <i>Cancer Treatment and Research</i> , 2011 , 157, 167-78	3.5	2

240	The myeloid growth factors. <i>Cancer Treatment and Research</i> , 2011 , 157, 109-25	3.5	1
239	Economic implications of 21-gene recurrence score assay: US multicenter experience. <i>Journal of Clinical Oncology</i> , 2010 , 28, e382; author reply e383	2.2	7
238	Reply to N. Lathia et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e764-e764	2.2	
237	Breast cancer screening: science, society and common sense. <i>Cancer Investigation</i> , 2010 , 28, 1-6	2.1	3
236	How we treat febrile neutropenia in patients receiving cancer chemotherapy. <i>Journal of Oncology Practice</i> , 2010 , 6, 149-52	3.1	26
235	A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. <i>Cancer Investigation</i> , 2010 , 28, 978-82	2.1	57
234	Availability of experimental therapy outside oncology randomized clinical trials in the United States. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5067-73	2.2	12
233	Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. <i>Thrombosis Research</i> , 2010 , 126, 113-8	8.2	91
232	Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. <i>Thrombosis Research</i> , 2010 , 125 Suppl 2, S120-7	8.2	34
231	Anthracyclines in the treatment of early-stage breast cancer: ally or adversary?. <i>Cancer Investigation</i> , 2010 , 28, 217-9	2.1	2
230	Comparative effectiveness research and genomic personalized medicine. <i>Personalized Medicine</i> , 2010 , 7, 223-227	2.2	5
229	Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2914-24	2.2	143
228	Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 121, 771-6	4.4	2
227	Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. <i>Journal of Hematology and Oncology</i> , 2010 , 3, 27	22.4	12
226	Risk of mortality in patients with cancer who experience febrile neutropenia. <i>Cancer</i> , 2010 , 116, 5555-636.4		160
225	Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74, 203-10	7	26
224	Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer. <i>Cancer Investigation</i> , 2009 , 27, 885-90	2.1	6
223	Preventing venous thromboembolism in cancer patients: can we do better?. <i>Journal of Oncology Practice</i> , 2009 , 5, 165-6	3.1	1

222	Comparative effectiveness research in oncology: the need for clarity, transparency and vision. <i>Cancer Investigation</i> , 2009 , 27, 593-7	2.1	14
221	Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. <i>Cancer Investigation</i> , 2009 , 27, 953-9	2.1	19
220	Cancer, clots and consensus: new understanding of an old problem. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4821-6	2.2	120
219	Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 543-5	9.7	2
218	Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. <i>Clinical Therapeutics</i> , 2009 , 31, 1092-104	3.5	54
217	Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. <i>Cancer</i> , 2009 , 115, 2660-70	6.4	59
216	Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. <i>Cancer</i> , 2009 , 115, 5319-28	6.4	35
215	Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. <i>Cancer</i> , 2009 , 115, 5637-50	6.4	28
214	Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. <i>Value in Health</i> , 2009 , 12, 217-25	3.3	41
213	Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. <i>Current Medical Research and Opinion</i> , 2009 , 25, 401-11	2.5	49
212	Cancer and thrombosis: back to the future renewed interest in an old problem. <i>Cancer Investigation</i> , 2009 , 27, 472-3	2.1	7
211	Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4919-26	2.2	133
210	Impact of chemotherapy dose intensity on cancer patient outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 99-108	7.3	200
209	NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 1060-96	7.3	255
208	Myeloid growth factors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 64-83	7.3	44
207	Low Molecular Weight Heparin Thromboprophylaxis in Ambulatory Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. <i>Blood</i> , 2009 , 114, 490-490	2.2	11
206	Impact of Decision-Support On Clinicians' Assessment of Febrile Neutropenia Risk.. <i>Blood</i> , 2009 , 114, 1409-1409	2.2	
205	Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. <i>Value in Health</i> , 2008 , 11, 172-9	3.3	61

204	Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. <i>Human Pathology</i> , 2008 , 39, 386-92	3.7	53
203	Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. <i>Archives of Internal Medicine</i> , 2008 , 168, 2377-81		237
202	Caring for the elderly cancer patient: training the next generation of oncologists. <i>Journal of Oncology Practice</i> , 2008 , 4, 193-4	3.1	2
201	Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 1574-87	27.4	79
200	Recommendations on the use of 18F-FDG PET in oncology. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 480-508	9	814
199	Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5797-801	2.2	85
198	American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4022-6	2.2	47
197	ASCO Clinical Practice Guidelines: Past, Present and Future. <i>Journal of Oncology Practice</i> , 2008 , 4, 236-7	3.1	3
196	Development and validation of a predictive model for chemotherapy-associated thrombosis. <i>Blood</i> , 2008 , 111, 4902-7	2.2	1243
195	Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008 , 6, 109-18	7.3	173
194	Undertreatment of cancer patients with chemotherapy is a global concern. <i>Journal of Oncology Practice</i> , 2008 , 4, 114-5	3.1	7
193	The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008 , 6, 942-953	7.3	35
192	Reply to Frequency, Risk Factors, and Trends for Venous Thromboembolism Among Hospitalized Cancer Patients. <i>Cancer</i> , 2008 , 113, 224-224	6.4	1
191	Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 72, 24-33	4	98
190	Venous Thromboembolism Risk Model Predicts Early Progression and Overall Mortality in Cancer Patients Receiving Chemotherapy. <i>Blood</i> , 2008 , 112, 172-172	2.2	6
189	Standard Versus Dose-Intensified Chemotherapy with Granulocyte Colony-Stimulating Factor for Malignant Lymphoma: Evaluation of Risk for Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Blood</i> , 2008 , 112, 2390-2390	2.2	2
188	Risk Prediction of Chemotherapy-Associated Toxicity in Patients Receiving Cancer Chemotherapy. <i>Translational Medicine Series</i> , 2008 , 1-23		
187	Neutropenia and Its Complications. <i>Translational Medicine Series</i> , 2008 , 1-19		

186	Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia 2008 , 509-530		1
185	Optimal cancer care across the spectrum of life and disease. <i>American Journal of Managed Care</i> , 2008 , 14, 262-4	2.1	
184	Variation in the cost of medications for the treatment of colorectal cancer. <i>American Journal of Managed Care</i> , 2008 , 14, 717-25	2.1	27
183	Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3158-67	2.2	522
182	Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2007 , 23, 2283-95	2.5	127
181	Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. <i>Cancer</i> , 2007 , 109, 1011-8	6.4	154
180	A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. <i>Cancer</i> , 2007 , 110, 1149-61	6.4	176
179	Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. <i>Cancer</i> , 2007 , 110, 1611-20	6.4	99
178	Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. <i>Cancer</i> , 2007 , 110, 2339-46	6.4	541
177	The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. <i>Transfusion</i> , 2007 , 47, 573-81	2.9	79
176	Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5, 632-4	15.4	968
175	Economic Analysis of Gene Expression Profile Data to Guide Adjuvant Treatment in Women with Early-Stage Breast Cancer. <i>Translational Medicine Series</i> , 2007 , 147-158		
174	Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 277-84	2.2	92
173	Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2522-7	2.2	107
172	ASCO Clinical Practice Guidelines and Beyond. <i>Journal of Oncology Practice</i> , 2007 , 3, 330-1	3.1	4
171	Economics of cancer care. <i>Journal of Oncology Practice</i> , 2007 , 3, 113-4	3.1	7
170	Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 217-28	7.3	20
169	Granulocyte colony-stimulating factors: finding the right indication. <i>Current Opinion in Oncology</i> , 2007 , 19, 299-307	4.2	22

168	Ductal carcinoma in situ: a review of recent advances. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007 , 19, 63-7	2.4	13
167	American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5490-505	2.2	749
166	Agents under investigation for the treatment and prevention of neutropenia. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 1831-40	5.9	6
165	Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. <i>Pharmacoeconomics</i> , 2007 , 25, 343-51	4.4	23
164	A Conditional Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.. <i>Blood</i> , 2007 , 110, 372-372	2.2	1
163	Cost-Effectiveness of Primary Prophylaxis with Pegfilgrastim Versus Filgrastim in Non-Hodgkin's Lymphoma Patients Receiving CHOP-21.. <i>Blood</i> , 2007 , 110, 5166-5166	2.2	1
162	Myeloid growth factors. Clinical practice guidelines in oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 188-202	7.3	47
161	Estimating net benefits and harms of screening mammography in women age 40 to 49 years. <i>Annals of Internal Medicine</i> , 2007 , 147, 882	8	1
160	Gene Expression Profile Assays as Predictors of Distant Recurrence-Free Survival in Early-Stage Breast Cancer. <i>Translational Medicine Series</i> , 2007 , 137-146		
159	Risks and consequences of chemotherapy-induced neutropenia. <i>Clinical Cornerstone</i> , 2006 , 8 Suppl 5, S12-8		25
158	Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. <i>Cancer</i> , 2006 , 106, 4-16	6.4	657
157	Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. <i>Cancer</i> , 2006 , 106, 223-33	6.4	39
156	Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. <i>Cancer</i> , 2006 , 106, 2258-66	6.4	789
155	Burden of pancreatic cancer and disease progression: economic analysis in the US. <i>Oncology</i> , 2006 , 70, 71-80	3.6	22
154	Thromboembolism in hospitalized neutropenic cancer patients. <i>Journal of Clinical Oncology</i> , 2006 , 24, 484-90	2.2	364
153	Withholding antibiotics from patients with febrile neutropenia. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1221-2; author reply 1222-3	2.2	4
152	Venous thromboembolism in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1029-33	1.9	75
151	Screening mammography at 40-49 years: regret or no regret?. <i>Lancet, The</i> , 2006 , 368, 2035-7	4.0	124

150	Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis. <i>Clinical Breast Cancer</i> , 2006 , 7, 372-9	3	24
149	Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2006 , 32, 289-303	14.4	46
148	2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3187-205	2.2	1358
147	Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2006 , 100, 255-62	4.4	112
146	Pegfilgrastim Provides Effective Primary Prophylaxis Against Febrile Neutropenia in Patients with NHL Undergoing Chemotherapy: Initial Results from an Integrated Analysis - The Neulasta Versus Current Neutropenia Management Practice (Neucup) Project.. <i>Blood</i> , 2006 , 108, 1150-1150	2.2	1
145	Prospective Validation of a Predictive Model for Early Anemia in Patients Receiving Cancer Chemotherapy.. <i>Blood</i> , 2006 , 108, 460-460	2.2	1
144	Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia. <i>Oncology</i> , 2006 , 20, 16-20	1.8	1
143	Chemotherapy dose intensity and quality cancer care. <i>Oncology</i> , 2006 , 20, 16-25	1.8	41
142	A primer in prognostic and predictive models: development and validation of neutropenia risk models. <i>Supportive Cancer Therapy</i> , 2005 , 2, 168-75		6
141	Moving beyond febrile neutropenia. <i>Supportive Cancer Therapy</i> , 2005 , 2, 95-7		2
140	The impact of anaemia and its treatment on employee disability and medical costs. <i>Pharmacoeconomics</i> , 2005 , 23, 183-92	4.4	21
139	Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4198-214	2.2	234
138	American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7703-20	2.2	1404
137	The challenge of systematic reviews of diagnostic and staging studies in cancer. <i>Cancer Treatment Reviews</i> , 2005 , 31, 628-39	14.4	8
136	Hemopoiesis and aging. <i>Cancer Treatment and Research</i> , 2005 , 124, 109-34	3.5	19
135	Time is money for both the healthy and the sick. <i>Medical Care</i> , 2005 , 43, 637-9	3.1	9
134	Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005 , 3, 557-71	7.3	78
133	The economic burden of anemia in cancer patients receiving chemotherapy. <i>Value in Health</i> , 2005 , 8, 149-56	3.3	56

132	Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. <i>Value in Health</i> , 2005 , 8, 47-52	3.3	25
131	The strengths and limitations of meta-analyses based on aggregate data. <i>BMC Medical Research Methodology</i> , 2005 , 5, 14	4.7	154
130	Use of re-randomized data in meta-analysis. <i>BMC Medical Research Methodology</i> , 2005 , 5, 17	4.7	14
129	Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. <i>Cancer</i> , 2005 , 104, 2822-9	6.4	379
128	Length of stay and mortality associated with febrile neutropenia among children with cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7958-66	2.2	102
127	Undertreatment of obese women receiving breast cancer chemotherapy. <i>Archives of Internal Medicine</i> , 2005 , 165, 1267-73		202
126	Risk models for predicting chemotherapy-induced neutropenia. <i>Oncologist</i> , 2005 , 10, 427-37	5.7	234
125	Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5, 1635-46	5.4	33
124	Up-Front Therapy for Multiple Myeloma: A Survey of Practice Patterns in the USA.. <i>Blood</i> , 2005 , 106, 5172-5172	2.2	1
123	Myeloid growth factors clinical practice guidelines in oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005 , 3, 540-55	7.3	24
122	A Prospective Risk Model for Neutropenic Complications in Patients with Malignant Lymphoma.. <i>Blood</i> , 2005 , 106, 3328-3328	2.2	
121	A Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.. <i>Blood</i> , 2005 , 106, 754-754	2.2	
120	Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. <i>American Journal of Managed Care</i> , 2005 , 11, 313-24	2.1	162
119	The colony-stimulating factors: use to prevent and treat neutropenia and its complications. <i>Expert Opinion on Biological Therapy</i> , 2004 , 4, 1897-910	5.4	29
118	Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4302-11	2.2	253
117	Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. <i>Pharmacotherapy</i> , 2004 , 24, 488-94	5.8	37
116	A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2004 , 85, 143-50	4.4	13
115	Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. <i>Supportive Care in Cancer</i> , 2004 , 12, 543-9	3.9	93

114	Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. <i>Cancer</i> , 2004 , 100, 228-37	6.4	574
113	Benefits of GM-CSF Versus Placebo or G-CSF in Reducing Chemotherapy-Induced Complications: A Systematic Review of the Literature. <i>Supportive Cancer Therapy</i> , 2004 , 2, 34-41		14
112	Prophylactic pegfilgrastim significantly reduces febrile neutropenia during moderately myelosuppressive chemotherapy. <i>Supportive Cancer Therapy</i> , 2004 , 1, 207-9		1
111	Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. <i>American Journal of Medicine</i> , 2004 , 116, 28-34	2.4	17
110	First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.. <i>Blood</i> , 2004 , 104, 2210-2210	2.2	7
109	Gene Expression Profile Signatures to Predict Survival in Diffuse Large B-Cell Lymphoma: A Meta-Analysis of Early Results.. <i>Blood</i> , 2004 , 104, 2274-2274	2.2	2
108	Venous Thromboembolic Events in Patients with Diffuse Large B cell Non- Hodgkin's Lymphoma.. <i>Blood</i> , 2004 , 104, 4542-4542	2.2	2
107	Thromboembolism in Hospitalized Neutropenic Cancer Patients.. <i>Blood</i> , 2004 , 104, 2199-2199	2.2	
106	Assessment of Clinical Outcomes Following Erythropoietic Intervention at a Hemoglobin Concentration above 10 g/dL: A Comprehensive Review of Recent Literature.. <i>Blood</i> , 2004 , 104, 3714-3714	2.2	2
105	Predicting the Risk of Neutropenic Complications and Reduced Dose Intensity in Patients with Malignant Lymphoma: Results from a Prospective Study.. <i>Blood</i> , 2004 , 104, 4599-4599	2.2	
104	Prophylactic Colony-Stimulating Factors in Pediatric Patients Receiving Myelosuppressive Chemotherapy: A Meta-Analysis of Randomized Controlled Trials.. <i>Blood</i> , 2004 , 104, 2211-2211	2.2	0
103	Economics of Hematopoietic Growth Factors 2004 , 409-443		5
102	Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. <i>Leukemia and Lymphoma</i> , 2003 , 44, 2069-76	1.9	177
101	Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003 , 1, 440-54	7.3	66
100	Evidence-based use of colony-stimulating factors in elderly cancer patients. <i>Cancer Control</i> , 2003 , 10, 487-99	2.2	45
99	Balancing the benefits and costs of colony-stimulating factors: a current perspective. <i>Seminars in Oncology</i> , 2003 , 30, 10-7	5.5	23
98	Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. <i>Cancer</i> , 2003 , 98, 2402-9	6.4	136
97	The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. <i>BMC Nursing</i> , 2003 , 2, 2	3.2	16

96	Evidence-based oncology in cancer treatment reviews. <i>Cancer Treatment Reviews</i> , 2003 , 29, 45-50	14.4	1
95	Epidemiology of febrile neutropenia. <i>Supportive Cancer Therapy</i> , 2003 , 1, 23-35		77
94	Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4524-31	2.2	364
93	Colony stimulating factors for chemotherapy induced febrile neutropenia. <i>Cochrane Database of Systematic Reviews</i> , 2003 , CD003039		18
92	Cost effectiveness of myeloid growth factors in cancer chemotherapy. <i>Psychophysiology</i> , 2003 , 2, 471-9		6
91	Risk assessment in oncology clinical practice. From risk factors to risk models. <i>Oncology</i> , 2003 , 17, 8-13	1.8	9
90	G-CSF as prophylaxis of febrile neutropenia in SCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 1273-84		20
89	Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. <i>Current Opinion in Hematology</i> , 2002 , 9, 207-14	3.3	40
88	Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. <i>American Journal of Medicine</i> , 2002 , 112, 406-11	2.4	186
87	Overlooking patient outcomes in a meta-analysis of trials of granulocyte colony-stimulating factor. <i>American Journal of Medicine</i> , 2002 , 113, 766-768	2.4	
86	Filgrastim in patients with neutropenia: potential effects on quality of life. <i>Drugs</i> , 2002 , 62 Suppl 1, 65-78	2.1	36
85	Exercise Prescription. <i>Annals of Internal Medicine</i> , 2002 , 136, 564		8
84	Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3622-34	2.2	2077
83	Economic analysis of randomized, controlled trials. <i>Current Oncology Reports</i> , 2001 , 3, 396-403	6.3	5
82	Understanding economic analyses. <i>Evidence-based Oncology</i> , 2001 , 2, 2-5		7
81	Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1583-5	2.2	66
80	Hematopoietic growth factors in the older cancer patient. <i>Current Opinion in Hematology</i> , 2001 , 8, 170-83	3.3	46
79	Cancer in the Elderly. <i>Annals of Internal Medicine</i> , 2001 , 134, 800		8

78	Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. <i>Annals of Surgery</i> , 2000 , 231, 795-803	7.8	93
77	Evidentiary challenges to evidence-based medicine. <i>Journal of Evaluation in Clinical Practice</i> , 2000 , 6, 99-109	2.5	28
76	Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. <i>Journal of Pain and Symptom Management</i> , 2000 , 19, 436-45	4.8	90
75	Understanding treatment benefits and harms. <i>Evidence-based Oncology</i> , 2000 , 1, 66-68		3
74	A predictive model for neutropenia associated with cancer chemotherapy. <i>Pharmacotherapy</i> , 2000 , 20, 104S-111S	5.8	24
73	Quality of life after adjuvant chemotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2000 , 62, 141-50	4.4	119
72	Hemopoietic reserve in the older cancer patient: clinical and economic considerations. <i>Cancer Control</i> , 2000 , 7, 539-47	2.2	64
71	What threshold for adjuvant therapy in older breast cancer patients?. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1709-17	2.2	179
70	Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer. <i>Annual Review of Medicine</i> , 2000 , 51, 525-42	17.4	71
69	The uncertainty principle and industry-sponsored research. <i>Lancet, The</i> , 2000 , 356, 635-8	4.0	359
68	Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 907-14	15.1	136
67	Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. <i>Journal of Pain and Symptom Management</i> , 1999 , 18, 233-42	4.8	282
66	Update of the economic analyses of the use of the colony-stimulating factors. <i>Current Opinion in Hematology</i> , 1999 , 6, 145-51	3.3	21
65	Methodological challenges in the evaluation of prognostic factors in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1998 , 52, 289-303	4.4	207
64	Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma. <i>Annals of Surgical Oncology</i> , 1998 , 5, 376-83	3.1	15
63	Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. <i>Annals of Surgical Oncology</i> , 1998 , 5, 522-8	3.1	55
62	Molecular staging of malignant melanoma: correlation with clinical outcome. <i>JAMA - Journal of the American Medical Association</i> , 1998 , 280, 1410-5	27.4	287
61	Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia. <i>Current Opinion in Oncology</i> , 1998 , 10, 291-6	4.2	19

60	Comorbidity and functional status are independent in older cancer patients. <i>Journal of Clinical Oncology</i> , 1998 , 16, 1582-7	2.2	813
59	Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. <i>Journal of Clinical Oncology</i> , 1998 , 16, 1689-96	2.2	390
58	Cancer Care in the Elderly: Cost and Quality-of-Life Considerations. <i>Cancer Control</i> , 1998 , 5, 347-354	2.2	17
57	Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. <i>Annals of Surgery</i> , 1998 , 227, 645-51; discussion 651-3	7.8	462
56	Sentinel lymph node biopsy in melanoma of the head and neck. <i>Plastic and Reconstructive Surgery</i> , 1997 , 100, 591-4	2.7	135
55	Cancer in the Elderly: Epidemiologic and Clinical Implications. <i>Clinics in Geriatric Medicine</i> , 1997 , 13, 1-14	3.8	40
54	The Role of Selective Lymphadenectomy in Breast Cancer. <i>Cancer Control</i> , 1997 , 4, 211-219	2.2	12
53	Menopausal Status and the Impact of Early Recurrence on Breast Cancer Survival. <i>Cancer Control</i> , 1997 , 4, 335-341	2.2	5
52	Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: clinical outcome. <i>Annals of Surgical Oncology</i> , 1997 , 4, 644-9	3.1	37
51	Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. <i>Annals of Surgical Oncology</i> , 1997 , 4, 198-202	3.1	36
50	Importance of race on breast cancer survival. <i>Annals of Surgical Oncology</i> , 1997 , 4, 80-7	3.1	40
49	Use of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study: Breast Cancer patients receiving adjuvant chemotherapy can safely continue on full-dose intensity therapy using supportive treatment with recombinant G-CSF.. <i>Cancer Control</i> , 1996 , 3, 1-4	2.2	20
48	Evaluation of new putative tumor markers for melanoma. <i>Annals of Surgical Oncology</i> , 1996 , 3, 558-63	3.1	52
47	Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. <i>Annals of Surgery</i> , 1996 , 223, 217-24	7.8	391
46	Timing of weight gain and breast cancer risk. <i>Cancer</i> , 1995 , 76, 243-9	6.4	57
45	The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. <i>Cancer</i> , 1995 , 76, 1634-42	6.4	105
44	Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer. <i>Clinical Infectious Diseases</i> , 1994 , 18, S189-S196	11.6	6
43	Age as a prognostic factor in the malignant melanoma population. <i>Annals of Surgical Oncology</i> , 1994 , 1, 487-94	3.1	113

42	The effect of changing disease risk on clinical reasoning. <i>Journal of General Internal Medicine</i> , 1994 , 9, 488-95	4	33
41	The orderly progression of melanoma nodal metastases. <i>Annals of Surgery</i> , 1994 , 220, 759-67	7.8	573
40	Overestimation of test effects in clinical judgment. <i>Journal of Cancer Education</i> , 1993 , 8, 297-307	1.8	29
39	Variation in body fat distribution and breast cancer risk in the families of patients with breast cancer and control families. <i>Cancer</i> , 1993 , 71, 2764-8	6.4	8
38	A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. <i>Journal of Clinical Oncology</i> , 1992 , 10, 257-63	2.2	495
37	Advances in current cancer treatment: an overview. <i>Hematological Oncology</i> , 1992 , 10, 3-6	1.3	1
36	Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma. <i>Hematological Oncology</i> , 1992 , 10, 61-74	1.3	5
35	RISK FACTORS FOR CANCER. <i>Primary Care - Clinics in Office Practice</i> , 1992 , 19, 465-479	2.2	10
34	Breast cancer of the older woman: an annotated review. <i>Journal of the American Geriatrics Society</i> , 1991 , 39, 1113-23	5.6	14
33	A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. <i>Cancer</i> , 1991 , 67, 245-9	6.4	19
32	Obesity and body fat distribution and breast cancer prognosis. <i>Cancer</i> , 1991 , 67, 523-8	6.4	61
31	Obesity, body fat distribution, and sex hormones in breast cancer patients. <i>Cancer</i> , 1991 , 67, 2215-8	6.4	57
30	Estimate of breast cancer risk reduction with weight loss. <i>Cancer</i> , 1991 , 67, 2622-5	6.4	24
29	Concentrated albumin infusion as an aid to postoperative recovery after pelvic exenteration. <i>Gynecologic Oncology</i> , 1991 , 43, 265-9	4.9	12
28	Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. <i>New England Journal of Medicine</i> , 1991 , 325, 164-70	59.2	1179
27	The Effect of Duration of Intervention and Locus of Control on Dietary Change. <i>American Journal of Preventive Medicine</i> , 1991 , 7, 341-347	6.1	10
26	Serum cholesterol reduction with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 1990 , 17, 3-7	4.4	30
25	Abdominal obesity and breast cancer risk. <i>Annals of Internal Medicine</i> , 1990 , 112, 182-6	8	131

24	The value of current nutrition information. <i>Preventive Medicine</i> , 1990 , 19, 45-53	4.3	22
23	Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells. <i>In Vitro Cellular & Developmental Biology</i> , 1989 , 25, 297-302		41
22	Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. <i>Gynecologic Oncology</i> , 1989 , 35, 75-7	4.9	19
21	Relation of results of exercise stress tests in young women to phases of the menstrual cycle. <i>American Journal of Cardiology</i> , 1988 , 61, 197-9	3	35
20	Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide. <i>Gynecologic Oncology</i> , 1988 , 29, 32-6	4.9	11
19	Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988 , 85, 1028-32	11.5	334
18	Lung cancer in Florida. Risks associated with residence in the central Florida phosphate mining region. <i>American Journal of Epidemiology</i> , 1988 , 128, 78-84	3.8	6
17	Cigarette smoking and the risk of female reproductive cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1987 , 157, 35-40	6.4	72
16	Leukemia and Radium Groundwater Contamination-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1986 , 255, 902	27.4	
15	Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck. <i>Head & Neck</i> , 1986 , 9, 104-10		73
14	Peritoneal cytology and invasive carcinoma of the cervix. <i>Gynecologic Oncology</i> , 1986 , 24, 331-6	4.9	15
13	Digitalis use in a retirement community. <i>Journal of the American Geriatrics Society</i> , 1986 , 34, 504-6	5.6	2
12	Factors affecting the incidence of infectious morbidity after radical hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 1985 , 152, 817-21	6.4	33
11	High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984 , 7, 361-3	2.7	3
10	Lithium carbonate in patients with small cell lung cancer receiving combination chemotherapy. <i>American Journal of Medicine</i> , 1981 , 70, 1222-9	2.4	35
9	The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy. <i>New England Journal of Medicine</i> , 1980 , 302, 257-60	59.2	98
8	The effect of lithium carbonate administration in patients with advanced small cell bronchogenic carcinoma receiving combination chemotherapy and radiotherapy. <i>Advances in Experimental Medicine and Biology</i> , 1980 , 127, 207-29	3.6	3
7	Fibrinogen kinetics in patients with neoplastic disease. <i>Cancer</i> , 1978 , 41, 1113-22	6.4	41

6	Combination chemotherapy and radiation therapy of undifferentiated small cell bronchogenic carcinoma. <i>Southern Medical Journal</i> , 1978 , 71, 519-24, 529	0.6	8
5	Acute myelogenous leukemia subsequent to therapy for a different neoplasm: clinical features and response to therapy. <i>American Journal of Hematology</i> , 1977 , 3, 209-18	7.1	49
4	Phospholipid membrane stabilization by dimethylsulfoxide and other inducers of Friend leukemic cell differentiation. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1976 , 448, 460-73	3.8	60
3	Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation. <i>Nature</i> , 1976 , 262, 361-3	50.4	203
2	The myeloid growth factors in older adults with cancer323-337		
1	Colony stimulating factors for afebrile neutropenia in cancer patients		1